Novo Holdings A/S’s Apogee Therapeutics APGE Stock Holding History

Novo Holdings A/S’s Portfolio APGE Stock Details APGE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-450,000	Closed	-$37.9M	–	26
2026 Q1	$37.9M	Sell	450,000 -120,000	-21%	-$8.71M	3.07%	14
2025 Q4	$43M	Buy	570,000 +70,000	+14%	+$4.41M	3.34%	11
2025 Q3	$19.9M	Buy	500,000 +50,608	+11%	+$1.93M	1.28%	22
2025 Q2	$19.5M	Buy	+449,392	New	+$17.1M	1.38%	21

Other funds holding APGE

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

GCL

Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return

Novo Holdings A/S's APGE Position: Q2 2026 in Review

Novo Holdings A/S sold out of Apogee Therapeutics (APGE) in Q2 2026, closing a stake of 450,000 shares — an estimated $37.9M sold.

Novo Holdings A/S first reported a position in APGE in Q2 2025 and held it in 4 quarters. The position peaked at $43M in Q4 2025. 289 funds tracked by Wall St. Rank hold APGE as of Q2 2026.

Novo Holdings A/S reported no remaining Apogee Therapeutics position as of Q2 2026 after selling out during the quarter.
Novo Holdings A/S sold 450,000 Apogee Therapeutics shares in Q2 2026, an estimated $37.9M.
Novo Holdings A/S first reported a position in Apogee Therapeutics in Q2 2025 and held it in 4 quarters.
Novo Holdings A/S's Apogee Therapeutics position peaked at $43M in Q4 2025.
289 funds tracked by Wall St. Rank held Apogee Therapeutics as of Q2 2026.

Based on Novo Holdings A/S's 13F filing for Q2 2026, filed 14 Aug 2026.